Abstract
To develop and characterize nanostructured formulations of tetracaine and to evaluate their antinociceptive activity in an in vivo model of formalin-induced orofacial pain. Microemulsions of tetracaine (MET) and its gelled version containing 4% chitosan (MEGT) were obtained. The formulations were characterized for particle size, polydispersity index (PDI), zeta potential (ZP), mucoadhesiveness, and in vitro release. In the in vivo study, forty-two female Wistar rats were allocated into seven groups (n = 6): control, eye drops (1% tetracaine + 0.1% phenylephrine), aqueous tetracaine solution (SOCT 1%), microemulsion without tetracaine, microemulsion with tetracaine (MET 1%), gelled microemulsion without tetracaine, and gelled microemulsion with tetracaine (MEGT 1%). Each animal received a topical application of the formulation in the right nostril, followed by a subcutaneous injection of 2% formalin. The formulations exhibited nanometric particle sizes (58.2–161.7 nm), high polydispersity indices (0.50–0.56), and distinct zeta potential values (–41.2 mV for MET and +19.7 mV for MEGT). MEGT showed higher firmness, consistency, and mucoadhesive properties compared to MET. In the release assays, both MET and MEGT provided sustained tetracaine release for up to 6 hours (30.74% and 28.52%, respectively). The tetracaine-containing formulations significantly reduced nociceptive behavior, maintaining low and stable rubbing times, with efficacy comparable to that of the tetracaine + phenylephrine eye drops (p > 0.05). It was possible to develop and characterize nanostructured tetracaine formulations with suitable physicochemical properties, sustained drug release, and effective antinociceptive activity. Both MET and MEGT proved to be promising alternatives to conventional eye drop formulations.